Vaxcyte’s Pneumococcal Vaccine Hits Primary Endpoints in Phase 3 Trial

Vaxcyte's pneumococcal vaccine has hit primary endpoints in a Phase 3 trial, setting up competition with Pfizer and Merck. The vaccine could be a significant player in the pharma market.